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Abstract
Background: Neurocysticercosis (NCC) is a major public health problem in many developing countries where health
education, sanitation, and meat inspection infrastructure are insufficient. The condition occurs when humans ingest eggs of
the pork tapeworm Taenia solium, which then develop into larvae in the central nervous system. Although NCC is endemic
in many areas of the world and is associated with considerable socio-economic losses, the burden of NCC remains largely
unknown. This study provides the first estimate of disability adjusted life years (DALYs) associated with NCC in Mexico.
Methods: DALYs lost for symptomatic cases of NCC in Mexico were estimated by incorporating morbidity and mortality due
to NCC-associated epilepsy, and morbidity due to NCC-associated severe chronic headaches. Latin hypercube sampling
methods were employed to sample the distributions of uncertain parameters and to estimate 95% credible regions (95%
CRs).
Findings: In Mexico, 144,433 and 98,520 individuals are estimated to suffer from NCC-associated epilepsy and NCC-
associated severe chronic headaches, respectively. A total of 25,341 (95% CR: 12,569–46,640) DALYs were estimated to be
lost due to these clinical manifestations, with 0.25 (95% CR: 0.12–0.46) DALY lost per 1,000 person-years of which 90% was
due to NCC-associated epilepsy.
Conclusion: This is the first estimate of DALYs associated with NCC in Mexico. However, this value is likely to be
underestimated since only the clinical manifestations of epilepsy and severe chronic headaches were included. In addition,
due to limited country specific data, some parameters used in the analysis were based on systematic reviews of the
literature or primary research from other geographic locations. Even with these limitations, our estimates suggest that
healthy years of life are being lost due to NCC in Mexico.
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Introduction
Neurocysticercosis (NCC) is a major public health problem
caused by the larvae of the zoonotic cestode Taenia solium. Humans
are the definitive hosts of T. solium and become infected with the
intestinal adult tapeworm (taeniasis) by ingesting undercooked
pork containing cysticerci. Humans can also become accidental
intermediate hosts after ingesting T. solium eggs leading to
cysticercosis and/or NCC, which occurs when larvae develop in
the central nervous system. A recent meta-analysis of published
studies on the frequency of NCC estimated that 29% (95% CI:
23%–36%) of epilepsy cases in NCC-endemic areas exhibit NCC
lesions as identified by brain neuroimaging [1]. NCC may also
manifest as migraine-type headaches and stroke, among others
[2,3].
NCC is common in many developing countries where health
education, sanitation, and meat inspection infrastructure are
insufficient [4]. This disease is predominantly found and
considered endemic in Latin American, Asian, and Sub-Saharan
African countries [5,6,7]. In Mexico, NCC is one of the main
causes of late onset epilepsy [8]. Very few studies have been
conducted to evaluate the burden of NCC [9,10] and there are no
estimates from Mexico. The disability adjusted life year (DALY),
developed for the Global Burden of Disease (GBD) Study, is the
most common metric used to measure disease burden. It combines
years of life lost due to premature mortality (YLL) and years of life
lost due to time lived in a disability state (YLD). One DALY is
considered the equivalent of one year of healthy life lost [11].
Two previous studies, both conducted in Africa, have evaluated
the burden of cysticercosis [9,10]. A study in Cameroon revealed
www.plosntds.org 1 February 2012 | Volume 6 | Issue 2 | e1521that the average number of DALYs lost due to NCC was 9.0 per
1,000 person-years (95% CR: 2.8–20.4) and the monetary burden
per case of cysticercosis amounted to 194 Euro (95% CR: 147–
253) [10]. This estimate only accounted for the disease burden due
to NCC-associated epilepsy and used serology for the diagnosis of
NCC. Another study conducted in South Africa estimated that the
monetary burden of NCC varied from US$ 632 to US$ 844 per
NCC-associated epilepsy case, indicating high financial losses
associated with this condition [9].
Studies are needed to estimate the burden of NCC in endemic
countries, such as Mexico, to facilitate international comparison of
disease burden and identify priorities for control. The research
presented here provides the first estimate of DALYs associated
with NCC in Mexico, incorporating two common clinical




This study was conducted in Mexico, which is the third largest
country in Latin America, with a 2005 population of almost 103
million and an annual population growth rate of 1.1% [13].
Traditional pig rearing practices in NCC endemic areas allow pigs
to have access to human feces in open fields facilitating the
completion of the T. solium life cycle [14].
Estimation of the prevalence of epilepsy in Mexico
Literature published through June 2011 was searched in
PubMed using the key words expressions ‘‘epilepsy AND
prevalence AND Mexico’’ and ‘‘epilepsy AND incidence AND
Mexico’’. Articles that were referenced in the literature identified
through the original search were also obtained and reviewed
(Figure 1). Community-based studies that employed door-to-door
surveys of households or surveys of school children were eligible
for inclusion if they were carried out by trained personnel using
standardized previously validated questionnaires. In addition, data
from systematic reviews and meta-analyses on epilepsy frequency
were included as appropriate. The identified literature was further
evaluated for epilepsy frequency data reported separately for
adults and children and for urban and rural areas. For the purpose
of this study, epilepsy was defined as the occurrence of at least two
unprovoked seizures separated by at least 24 hours [15].
The epilepsy prevalence estimates used in the current study
were based on estimates from Quet et al. (2011) [16]. This study
reported epilepsy prevalence for males and females in different age
groups (,15 years, 15–40 years, 41–60 years and .60 years) in a
rural community in the Puebla State of Mexico in 2007. For
analysis purposes, the prevalence estimates were applied to GBD
age groups as appropriate. Uncertainty was modeled with uniform
distributions using the upper and lower confidence intervals values
from the Quet et al. (2011) study. A systematic review of published
literature on epilepsy conducted in Latin America in 2005
reported that the prevalence of epilepsy in urban and rural areas
was not significantly different [17]. Since there were no
comparable data available specifically for Mexico, it was assumed
that the prevalence of epilepsy in urban and rural areas of Mexico
is also not significantly different.
Estimation of the number of NCC cases with epilepsy in
Mexico
A flowchart depicting how incidence of treated and untreated
NCC-associated epilepsy was determined is shown in Figure 2.
The number of cases of epilepsy was estimated by multiplying the
age and rural/urban stratified population size from the 2005
census [13] by the epilepsy prevalence estimates described above
[16]. While the prevalence of epilepsy in rural and urban areas of
Author Summary
Neurocysticercosis (NCC) is a major public health problem
caused by the larvae of the parasite Taenia solium. The
condition occurs when humans ingest eggs of the pork
tapeworm Taenia solium, which then develop into larvae in
the central nervous system. The disease is predominantly
found and considered important in Latin American, Asian,
and African countries and is associated with a large social
and economic burden. Very few studies have been
conducted to evaluate the burden of NCC and there are
no estimates from Mexico. We estimated the disability
adjusted life years (DALYs) lost due to NCC in Mexico
incorporating morbidity and mortality due to NCC-
associated epilepsy, and morbidity due to NCC-associated
severe chronic headaches. NCC-associated epilepsy and
severe chronic headaches were estimated to cause a loss
of approximately 0.25 healthy year of life per 1,000 persons
annually in Mexico. This is the first estimate of DALYs
associated with NCC in Mexico. However, this value is likely
to be underestimated since only the clinical manifestations
of epilepsy and severe chronic headaches were included.
Figure 1. Flowchart of study selection for the literature review of epilepsy prevalence in Mexico.
doi:10.1371/journal.pntd.0001521.g001
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associated epilepsy cases in urban and rural areas was assumed to
be different. This assumption was based on the only identified
study to look at the prevalence of NCC among patients with active
epilepsy in rural versus urban clusters [18]. Although the identified
study was conducted in the Vellore district of India, the difference
between urban and rural areas likely reflects a difference in T.
solium endemicity, which would also be found in Mexico. For
example, pig rearing practices used in the rural areas of Mexico
facilitate the completion of the T. solium life cycle.
The estimated proportion of epilepsy cases with NCC lesions
from a meta-analysis of NCC frequency data [1] was used for rural
areas of Mexico (Table 1). This value was chosen because the
meta-analysis used data from primarily rural endemic communi-
ties in countries such as Bolivia, Ecuador, Honduras, Burkina
Faso, and India to calculate the proportion of epilepsy cases with
Figure 2. Flowchart for estimating the incidence of NCC-associated epilepsy in Mexico. Note: Please refer to Table 1 for information
concerning the uncertainty distributions associated with the specific parameters. All data were stratified by rural/urban residence.
doi:10.1371/journal.pntd.0001521.g002
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NCC among patients with acute epilepsy in urban areas to be
approximately 0.52 times that in rural areas [18]. Since such
information is not available from Mexico, the lower and upper
confidence bounds of the proportion of children and adults with
NCC-associated epilepsy from the meta-analysis [1] were
multiplied by 0.52 to obtain the corresponding lower and upper
confidence bounds of the proportion of children and adults with
NCC-associated epilepsy in urban areas. The estimated numbers
of adults and children with epilepsy in rural and urban areas were
then multiplied by the respective proportion of people with
epilepsy with NCC lesions to obtain the number of NCC-
associated epilepsy cases in adults and children in rural and urban
areas.
A literature review was conducted to identify information on the
epilepsy treatment gap in Mexico. Literature published through
June 2011 was searched in PubMed using the key words
expression ‘‘epilepsy AND treatment gap AND Mexico’’. When
this search resulted in no usable data, a broader search using the
key words expression ‘‘epilepsy AND treatment gap’’ was
conducted. No literature was found that directly reported an
estimate of the epilepsy treatment gap in Mexico. However, a
2010 systematic review of the epilepsy treatment gap literature
worldwide was identified [22]. The authors of this systematic
Table 1. Epidemiological parameters used to calculate DALYs for NCC-associated epilepsy and severe chronic headaches in
Mexico.
Parameter
Value or range of
values Distribution References
2005 Population of Mexico (’000)
Urban areas 78,986 Fixed [13]
Rural areas 24,276 Fixed [13]
Total 103,263 Fixed [13]
Prevalence of epilepsy in 0–14 year old males in Mexico (per 1,000) 6.9 (1.4–12.5) Uniform
(1.4, 12.5)
[16]
Prevalence of epilepsy in 0–14 year old females in Mexico (per 1,000) 5.4 (0.8–10.0) Uniform
(0.8, 10.0)
[16]
Prevalence of epilepsy in 15–44 year old males in Mexico (per 1,000) 9.3 (1.4–17.2) Uniform
(1.4, 17.2)
[16]
Prevalence of epilepsy in 15–44 year old females in Mexico (per 1,000) 6.5 (1.4–11.7) Uniform
(1.4, 11.7)
[16]
Prevalence of epilepsy in 45–59 year old males and females in Mexico (per 1,000) 6.6 (0.1–13.2) Uniform
(0.1, 13.2)
[16]
Prevalence of epilepsy in males and females older than 60 years of age in Mexico (per 1,000) 15.5 (0.3–30.8) Uniform
(0.3, 30.8)
[16]
Proportion of epilepsy cases associated with NCC in individuals 0–14 years of age in urban areas of Mexico 0.13 (0.09–0.17) Uniform
(0.09, 0.17)
[1,18]
Proportion of epilepsy cases associated with NCC in individuals 0–14 years of age in rural areas of Mexico 0.25 (0.18–0.32) Uniform
(0.18,0.32)
[1]
Proportion of epilepsy cases associated with NCC in individuals older than 15 years of age
in urban areas of Mexico
0.15 (0.10–0.20) Uniform (0.10,0.20) [1,18]
Proportion of epilepsy cases associated with NCC in individuals older than 15 years of age
in rural areas of Mexico
0.28 (0.20–0.38) Uniform (0.20,0.38) [1]
Proportion of NCC patients 0–14 years of age with epilepsy 0.79 (0.70–0.86) Uniform
(0.70,0.86)
[22]
Proportion of NCC cases older than 15 years old with epilepsy 0.63 (0.52–0.74) Uniform
(0.52,0.74)
[22]
Proportion of epilepsy patients not receiving treatment in urban areas 0.39 (0.27–0.50) Uniform
(0.27,0.50)
[20]
Proportion of epilepsy patients not receiving treatment in rural areas 0.77 (0.68–0.87) Uniform
(0.68,0.87)
[20]
Proportion of 0–14 year-olds with severe headaches presenting with NCC 0.28 (0.21–0.35) Uniform
(0.21, 0.35)
[22]
Proportion of individuals older than 15 years of age with severe headaches presenting with NCC 0.28 (0.11–0.45) Uniform
(0.11,0.45)
[22]
Proportion of severe headaches patients not receiving treatment in urban areas 0.49 (0.37–0.60) Uniform
(0.37,0.60)
[20]
Proportion of severe headaches patients not receiving treatment in rural areas 0.87 (0.78–0.97) Uniform
(0.78,0.97)
[20]
Mortality due to epilepsy in Mexico (per 100,000 population) 1.5 Fixed [28]
doi:10.1371/journal.pntd.0001521.t001
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country income level (low, low middle, upper middle, and high) as
defined by the World Bank [19], as well as urban versus rural
location. Urban versus rural designation was based on the site
description in the methods sections of the manuscripts included in
the review. Based on data presented graphically in the epilepsy
treatment gap meta-analysis, it was estimated that 77% (95% CI:
67%–87%) and 38% (95% CI: 27%–50%) of people with epilepsy
in rural and urban areas, respectively, do not receive treatment
[20]. These values were used given the unavailability of such data
from Mexico. The number of NCC-associated epilepsy cases not
receiving treatment was estimated by multiplying the number of
NCC-associated epilepsy cases in rural and urban areas by the
respective percentage not receiving treatment according to the
epilepsy treatment gap meta-analysis [20]. Incidence of NCC-
associated epilepsy was estimated by dividing the prevalence of
NCC-associated epilepsy by the reported duration of epilepsy for
different age groups from the GBD study (Table 2) [21].
Estimation of the total number of clinical NCC cases seen
in Mexico
A recent systematic review and meta-analysis of the frequency
of the main clinical manifestations associated with NCC, using
documents published from January 1, 1990 to June 1, 2008, was
used to estimate the proportion of children and adults with
symptomatic NCC seen at neurological clinics that have epilepsy
as a clinical manifestation. This meta-analysis reported that 79%
(95% CI 70%–86%) of children (0–19 years old) and 63% (95%
CI 52%–74%) of adults with symptomatic NCC seen in
neurological clinics have epilepsy [22]. The total number of
symptomatic cases of NCC receiving care in neurology clinics was
calculated by dividing the number of NCC-associated epilepsy
cases who seek treatment (estimated in the previous section) by the
respective proportion of people with NCC that have epilepsy as a
clinical manifestation. This requires the assumption that all NCC
patients seeking treatment do so in neurology clinics.
Estimation of the number of NCC cases with severe
chronic headaches in Mexico
A flowchart depicting how incidence of treated and untreated
NCC-associated severe chronic headaches was determined is
shown in Figure 3. Severe chronic headaches were defined as
severe headaches that last for more than three continuous days.
The number of people with NCC-associated severe chronic
headaches who seek care was estimated by multiplying the total
estimated rural/urban stratified numbers of NCC cases who go to
neurology clinics (see previous section), by the proportion of NCC
cases attending neurology clinics with headaches based on the
systematic review of clinical manifestations associated with NCC
[22]. The total number of people with NCC-associated severe
chronic headaches in urban and rural areas was then calculated by
dividing the total number of NCC-associated severe chronic
Table 2. Disability weights and durations used to calculate NCC-associated DALYs in Mexico.
Parameter
Value or range of
values Distribution References
Epilepsy disability weight for people between 0 and 4 years of age not receiving an
appropriate treatment
0.099 (0.021–0.225) Beta(3,27.3) [10,21]
Epilepsy disability weight for people between 0 and 4 years of age receiving an
appropriate treatment
0.041 (0.003–0.124) Beta(1.5,35) [10,21]
Epilepsy disability weight for people older than 5 years of age not receiving an
appropriate treatment
0.15 (0.033–0.331) Beta(3,17) [10,21]
Epilepsy disability weight for people older than 5 years of age receiving an appropriate treatment 0.065 (0.004–0.192) Beta(1.5,21.6) [10,21]
Severe headaches disability weight for people not receiving an appropriate treatment 0.0275 (0.002–0.084) Beta(1.5,53.04) [27]
Severe headaches disability weight for people receiving an appropriate treatment 0.007 (0.000064–0.0290) Beta(0.75,106.4) [27]
Mean duration of disability due to epilepsy in males between 0 and 4 years of age 0.82 Fixed [21]
Mean duration of disability due to epilepsy in males between 5 and 14 years of age 2.64 Fixed [21]
Mean duration of disability due to epilepsy in males between 15 and 44 years of age 5.14 Fixed [21]
Mean duration of disability due to epilepsy in males between 45 and 59 years of age 2.33 Fixed [21]
Mean duration of disability due to epilepsy in males older than 60 years of age 1.16 Fixed [21]
Mean duration of disability due to epilepsy in females between 0 and 4 years of age 1.27 Fixed [21]
Mean duration of disability due to epilepsy in females between 5 and 14 years of age 3.41 Fixed [21]
Mean duration of disability due to epilepsy in females between 15 and 44 years of age 6.83 Fixed [21]
Mean duration of disability due to epilepsy in females between 45 and 59 years of age 6.73 Fixed [21]
Mean duration of disability due to epilepsy in females older than 60 years of age 3.5 Fixed [21]
Mean duration of disability due to severe headaches in males and females
between 0 and 4 years of age
4.28 Fixed [12]
Mean duration of disability due to severe headaches in males and females
between 5 and 14 years of age
4.28 Fixed [12]
Mean duration of disability due to severe headaches in males and females
between 15 and 44 years of age
4.28 Fixed [12]
Mean duration of disability due to severe headaches in males and females between 45 and 59 years of age 2.90 Fixed [12]
Mean duration of disability due to severe headaches in males and females older than 60 years of age 4.75 Fixed [12]
doi:10.1371/journal.pntd.0001521.t002
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www.plosntds.org 5 February 2012 | Volume 6 | Issue 2 | e1521Figure 3. Flowchart for estimating the incidence of NCC-associated severe chronic headaches in Mexico. Note: Please refer to Table 1
for information concerning the uncertainty distributions associated with the specific parameters. All data were stratified by urban/rural residence.
doi:10.1371/journal.pntd.0001521.g003
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proportion of NCC cases with severe chronic headaches [22].
Two scenarios were initially considered for the treatment gap for
severe chronic headaches. The first scenario assumed that the
epilepsy and severe chronic headaches treatment gaps were the same
and the second assumed a 10% difference in treatment gaps.
However, in the final analysis, the treatment gap for severe chronic
headaches was assumed to be 10% higher than that of epilepsy due to
the generally greater clinical severity of epilepsy. This estimate is
consistent with treatment gaps reported in other countries. For
example, studies conducted in the United Kingdom reported that the
epilepsy treatment gap was 2%, whereas the migraine treatment gap
was 14% [23,24]. Morillo et al. (2005) estimated that 48% of the
urban population of Mexico with severe headaches did not receive
treatment [25]. This estimate is similar to our estimate (49%). The
number of NCC-associated severe chronic headaches cases not
receiving treatment in Mexico was estimated by multiplying the
number of NCC-associated severe chronic headaches cases in rural
and urban areas of Mexicoby the respective estimated treatment gap.
The incidence of NCC-associated severe chronic headaches was
estimated by dividing the prevalence estimated above by the mean
duration of NCC-associated severe chronic headaches obtained
from chart reviews conducted at two referral neurological hospitals
in Mexico City [12]. Chart reviews captured information on
duration of NCC-associated severe chronic headaches in adults 18
years of age and older from the time of diagnosis to the date when
data were abstracted. The mean duration was calculated for each
GBD age group (Table 2). Since chart review data were not
available for children, a search of the literature was conducted to
identify NCC-associated headache duration data for this age group.
Literature published through June 2011 was searched in PubMed
using the key words expression ‘‘neurocysticercosis AND headache
AND duration’’. However, no information on duration of NCC-
associated headaches in children could be identified. Therefore,
duration of severe chronic headaches used for the 15–44 years age
group was also applied to the 0–15 years age group (Table 2).
Parameters for the estimation of DALYs lost due to NCC-
associated epilepsy and severe chronic headaches
The number of DALYs lost was calculated by adding the number
of years lived with a disability (YLD) to the number of years of life
lost due to mortality (YLL). The formulas used for the calculation of
YLD and YLL are shown in Eqs. 1 and 2 respectively:
YLD~I   DW   D ð1Þ
where I = age and sex specific estimates of incidence, DW =
disability weight, D = average duration of disability
YLL~N   L ð2Þ
where N=number of deaths per age-sex group, L=remaining life
expectancy at age of death [26].
The calculation of years of life lost due to time lived in a disability
state (YLD),requires the use of disability weights. Disability weightsfor
NCC were not included in the original GBD Study or its subsequent
updates. Therefore, disability weights for epilepsy provided by GBD
studies were used for NCC-associated epilepsy [21]. Disability weights
for severe chronic headaches were also not included in previous GBD
estimates, so published disability weights for migraine were used as a
surrogate [27]. Disability weights for epilepsy and severe chronic
headaches used in this study are listed in Table 2.
Years oflife lost duetopremature mortality(YLL) wereestimated
using standard life expectancies (life expectancy of 82.5 years at
birth for women and a life expectancy of 80.0 years at birth for men)
[26]. Three percent discounting and non uniform age weighting
(b=0.04 and C=0.1658) were applied [26]. These standard values
were chosen to compare our estimates to DALYs calculated for
other conditions in Mexico. World Health Organization (WHO)
2004 mortality rates for epilepsy in Mexico were used to calculate
the years of life lost due to premature NCC-associated epilepsy
mortality (YLL) [28]. The numbers of deaths of adults and children
with epilepsy in Mexico were multiplied by the respective
proportion of people with epilepsy with NCC lesions to obtain
NCC-associated epilepsy deaths [1]. A review of the literature was
conducted to identify data on NCC-associated headache deaths.
Literature published through June 2011 was searched in PubMed
using the key words expressions ‘‘neurocysticercosis AND headache
AND mortality’’ and ‘‘neurocysticercosis AND headache AND
death’’. However, no publications could be identified that evaluated
Table 3. Estimated numbers of people with NCC-associated
epilepsy and severe chronic headaches in Mexico.
NCC-associated manifestation Area Number 95% CR*
Epilepsy Urban 91,355 51,079–138,347
Rural 53,078 32,411–76,672
All 144,433 85,230–209,162





Table 4. Estimated annual incidence cases of NCC-associated epilepsy and severe chronic headaches in Mexico.
NCC-associated manifestation Area Number 95% CR* Incidence per 100,000 pop.
Epilepsy Urban 30,355 17,946–43,969 29.4
Rural 19,875 12,257–28,281 19.3
All 50,210 30,835–70,735 48.6
Severe chronic headaches Urban 13,069 5,288–26,295 12.7
Rural 12,183 2,826–38,217 11.8
All 25,253 9,310–57,537 24.5
*credible region.
doi:10.1371/journal.pntd.0001521.t004
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a lack of available data, we did not feel comfortable including an
estimate for NCC-associated headaches deaths.
Analysis
The number of DALYs lost due to NCC, with its 95% credible
region (95% CR), was estimated using @Risk (Palisade Corpora-
tion, Ithaca, NY, version 4.5). Latin Hypercube sampling was used
for uncertain parameters (distributions shown in Tables 1–2). The
model was run for 30,000 iterations to achieve convergence.
Uncertain epidemiological parameters were modeled using
uniform distributions, while disability weight uncertainty was
modeled using beta distributions. Regression sensitivity analysis
was conducted in @ Risk by varying the value of each parameter
to estimate its correlation to the total DALYs estimate. The
relative values of the regression coefficients indicate which
parameters had the greatest impact on the total DALYs estimate.
Results
Prevalence and annual incidence of NCC-associated
epilepsy and severe chronic headaches cases
Approximately 0.14% of the total population of Mexico was
estimated to have NCC-associated epilepsy and 0.08% was
estimated to have NCC-associated severe chronic headaches.
The estimated numbers of people in urban and rural areas with
NCC-associated epilepsy and severe chronic headaches, along
with 95% CRs, are reported in Table 3. Annual incident cases of
NCC-associated epilepsy and severe chronic headaches were 0.05
and 0.02 per 100 person-years, respectively (Table 4).
DALYs lost due to NCC-associated epilepsy and severe
chronic headaches
The total number of DALYs lost due to NCC-associated
epilepsy and severe chronic headaches in Mexico was estimated at
23,020 (95% CR: 11,283–43,276) and 2,321 (95% CR: 198–
8,754), respectively, with 0.25 (95% CR: 0.12–0.46) DALY lost
per 1,000 person-years (Figure 4). Twenty-eight percent of DALYs
lost due to NCC was attributed to YLL and the remaining 72%
was due to YLD (Table 5).
Sensitivity analysis
Based on the regression sensitivity analysis, the epilepsy
disability weights for untreated and for treated NCC in people
older than 5 years of age and the prevalence of epilepsy in 15–44
year-old males and females were the four parameters with the
greatest effect on the total DALYs estimate (Figure 5).
Discussion
This study represents only the second study to estimate the
burden of NCC using DALYs. The first, which was conducted in
Figure 4. Annual number of DALYs lost due to NCC-associated epilepsy and severe chronic headaches in Mexico. (A) DALYs lost due
to NCC-associated epilepsy. (B) DALYs lost due to NCC-associated severe chronic headaches. (C) DALYs lost due to NCC-associated epilepsy and
severe chronic headaches. Note: The bar height in the figure represents the estimated number of DALYs lost. The plot whiskers represent the 95% CR.
doi:10.1371/journal.pntd.0001521.g004
Table 5. Estimated annual number of DALYS due to NCC-associated epilepsy and severe chronic headaches in Mexico.
Source of DALYs Value (DALYs) 95%CR* Percentage of total DALYs
YLL in urban areas 4,439 3,262–5,818 18
YLL in rural areas 2,622 1,991–3,335 10
Total YLL 7,062 5,509–8,818 28
YLD in urban areas 10,143 3,063–22,920 40
YLD in rural areas 8,135 2,473–18,367 32
Total YLD 18,278 5,891–39,238 72
Total DALYs 25,341 12,569–46,640 100
DALYs per thousand persons 0.25 0.12–0.46
*credible region.
doi:10.1371/journal.pntd.0001521.t005
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alone [10]. The estimated number of DALYs lost per 1,000
person-years was higher in Cameroon (9.0) compared to Mexico
(0.25). One difference between the two studies is that all of our
data were stratified by urban/rural areas, age groups, and gender.
Such stratification was not used in the Cameroon study. Since the
majority of the Mexican population is urban, and the proportion
of epilepsy cases attributable to NCC is lower in urban areas, the
overall burden per person is expected to be lower in Mexico. In
addition, NCC-associated epilepsy patients were four times more
likely to receive treatment in Mexico than in Cameroon. Because
the disability weight for treated epilepsy is much lower than that
for untreated epilepsy, this results in fewer DALYS per 1,000
person-years.
Similarly, annual number of deaths due to NCC-associated
epilepsy was estimated to be higher (6.9% of the total annual
incident cases) in Cameroon compared to Mexico (0.5% of the
total annual incident cases). When the current model for Mexico
was run using the mortality rate from the Cameroon study, 1.08
(95% CR: 0.8–1.4) DALYs per 1,000 person-years were projected
to be lost compared to 0.25 (95% CR: 0.12–0.46) DALYs per
1,000 person-years. This suggests that the high mortality
associated with NCC-associated epilepsy in Cameroon had a
significant impact on disease burden in that country. Finally, the
estimated 9 DALYs lost per 1,000 person-years [10] due to NCC-
associated epilepsy in Cameroon is three times higher than the
2004 GBD estimate of 2.45 DALYs per 1,000 person-years due to
all cases of epilepsy in Cameroon [28]. This suggests that the
authors may have overestimated the burden of NCC associated
epilepsy in that country or else that the GBD estimates for epilepsy
were highly conservative.
According to 2004 GBD estimates, 1.7 DALYs per 1,000
person-years were estimated to be lost due to epilepsy in Mexico,
with approximately the same number of DALYs lost due to
migraine [28]. Our estimates for the number of DALYs lost per
1,000 person-years due to NCC was higher than such estimates for
other helminthic infections in Mexico (ascariasis-0.05, trichuriasis-
0.10, hookworm-0.03) due to the severity of clinical manifestations
associated with NCC and because NCC not only causes
morbidity, but also mortality in humans [28].
Our study has some limitations. The total estimated number of
DALYs lost was most likely underestimated since only the NCC-
associated clinical manifestations of epilepsy and severe chronic
headaches were included. There are many other clinical
manifestations of NCC [22] which could not be included largely
due to lack of information on frequency and disability weights.
Since data on the incidence of NCC-associated epilepsy and severe
chronic headaches were not available, the prevalence was divided
by the duration of symptoms to obtain an incidence value. In
addition, we assumed that the duration of epilepsy and severe
chronic headaches was the same among treated and untreated
cases, which is unlikely to be accurate. The mean duration of
NCC-associated severe chronic headaches was estimated from the
time of diagnosis to the end of symptoms based on the review of
medical charts of patients seeking care in tertiary hospitals of
Mexico City [12]. This may overestimate the true duration of
NCC-associated severe chronic headaches if only the most severe
cases are seen in tertiary hospitals. On the other hand, it could also
lead to an underestimation of the duration since people may wait a
long time before seeking care. Due to limited country-specific data,
parameters for the proportion of NCC patients with epilepsy and
severe chronic headaches and the epilepsy treatment gap were
based on systematic reviews of the literature [1,20,22].
Based on the regression sensitivity analysis, the disability weight
used for individuals with epilepsy who were greater than 4 years of
age was by far the most influential parameter. More precise values of
disability weights in future versions of the GBD should reduce the
uncertainty. The next most influential values were linked to the
prevalence of epilepsyin Mexico. The estimates used here werebased
on a single study that may not fully reflect the variation of prevalence
among the whole country. Better knowledge of the actual prevalence
of epilepsy in Mexico would also improve our estimates.
Figure 5. Sensitivity analysis of the total NCC-associated DALYs estimate for Mexico. Note: DW=Disability Weight.
doi:10.1371/journal.pntd.0001521.g005
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human health losses. However, Taenia solium cysticercosis not only
causes losses to human health, but also to pig farmers and their
communities. Therefore, the total societal burden is higher than
that estimated by the number of DALYs lost. An analysis of the
monetary burden of NCC in Mexico is currently underway and
will be presented in a later publication.
In conclusion, this is the first estimation of the non-monetary
burden of NCC in Mexico using the DALY. These estimates
suggest that healthy years of life continue to be lost annually in
Mexico, with a continued effort needed to control this parasitic
disease in endemic regions.
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